Director/PDMR Shareholding

Destiny Pharma PLC

26 May 2023

 

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 26 May 2023 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it was notified on 26 May 2023 that on that same day, Nick Rodgers, Chairman of the Company, purchased 20,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 30.19 pence.

Following the purchase, Mr. Rodgers' beneficial interest in the Company is 238,901 Ordinary Shares, representing 0.25 per cent. of the total issued share capital.

For further information, please contact: 

Destiny Pharma plc 

Dr Debra Barker, CEO

Shaun Claydon, CFO 

[phone] 

[e-mail] 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

[phone]

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

Optimum Strategic Communications 

Mary Clark / Nick Bastin / Jonathan Edwards / Eleanor Cooper

[phone]

[e-mail] 

MC Services AG

Anne Hennecke / Andreas Burckhardt

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the Company, please visit  https://www.destinypharma.com

Further information is disclosed below pursuant to Article 19(3) of the Market Abuse Regulation.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nick Rodgers
2.	Reason for the Notification
a)	Position/status	Chairman
b)	Initial notification/Amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 1 pence each in Destiny Pharma Plc
	Identification code	GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 30.1898 pence 20,000
d)	Aggregated information: ·      Aggregated volume ·      Price	See 4c) above
e)	Date of the transaction	26 May 2023
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

 

END